MapLight Therapeutics, Inc. MPLT
- betovumeline — Schizophrenia Phase 2
- betovumeline — Alzheimer's Disease Psychosis Phase 2
- ML-055 Preclinical
Home › Targets › M1 muscarinic receptor
M1 muscarinic receptor (1 companies · 3 programs)
Companies with an active program directed at M1 muscarinic receptor.